Abstracts tagged "interstitial lung disease"

Abstract Number: 2375 • 2015 ACR/ARHP Annual Meeting
Interstitial Lung Disease in Patients with Anti-PM-Scl Antibody
Hiromichi Tamaki¹, Ruchi Yadav², James Bena³ and Soumya Chatterjee⁴, ¹Department of Rheumatic and Immunologic Diseases, Cleveland Clinic Foundation, Cleveland, OH, ²Diagnostic Radiology, Cleveland Clinic, Cleveland, OH, ³Department of Quantitative Health Sciences, Cleveland Clinic Foundation, Cleveland, OH, ⁴Cleveland Clinic Foundation, Cleveland, OH
Background/Purpose: Patients with anti-PM-Scl antibody (PM-Scl) can present with several different phenotypes: polymyositis (PM), dermtomyositis (DM), systemic sclerosis (SSc), scleromyositis, or sclero-dermatomyositis. Interstitial Lung Disease…
Abstract Number: 2611 • 2015 ACR/ARHP Annual Meeting
Circulating Monocyte Count Is Significantly Associated with Interstitial Pneumonia in Biologic-Naive Patients with Rheumatoid Arthritis: A Single-Center Prospective Cohort Study (Keio First-Bio Cohort Study)
Keisuke Izumi¹, Misato Hashizume², Yuko Kaneko³, Keiko Yoshimoto¹ and Tsutomu Takeuchi¹, ¹Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan, ²Product Research Department, Fuji-Gotemba Research Laboratories, Chugai Pharmaceutical Co., Ltd., Gotemba, Japan, ³Division of Rheumatology, Keio University School of Medicine, Tokyo, Japan
Background/Purpose : Interstitial pneumonia (IP) is one of the most critical complications in rheumatoid arthritis (RA). Severe IP is developed in zymosan-treated SKG mice, and…
Abstract Number: 288 • 2015 ACR/ARHP Annual Meeting
Myositis Associated Interstitial Lung Disease: Clinical Predictors of Failure to Conventional Treatment and Their Response to Tacrolimus
Niharika Sharma¹, Anisha Dua¹, Michael Putman², Rekha Vij³ and Mary Strek³, ¹Rheumatology, The University of Chicago, Chicago, IL, ²Internal Medicine, The University of Chicago, Chicago, IL, ³Pulmonology, The University of Chicago, Chicago, IL
Background/Purpose: Interstitial lung disease (ILD) frequently complicates Polymyositis (PM) and Dermatomyositis (DM) and accounts for significant morbidity and mortality in affected patients. Patients with Myositis…
Abstract Number: 2962 • 2015 ACR/ARHP Annual Meeting
Efficacy of Mycophenolate As a Maintenance Therapy Following the Administration of Cyclophosphamide in the Treatment of Interstitial Lung Disease Associated with Systemic Sclerosis
Javier Narváez¹, Helena Borrell Paños², Ivan Castellvi³, Sergi Heredia², Milena Millan³, Susana Herrera⁴, Eulalia Armengol², Josep María LLobet³, Joan Miquel Nolla², María Molina⁵ and Juan José Alegre⁶, ¹Rheumatology, Hospital Universitario de Bellvitge, Barcelona, Spain, ²Department of Rheumatology, Hospital Universitario de Bellvitge, Barcelona, Spain, ³Rheumatology Unit. Hospital de la Santa Creu i Sant Pau, Barcelona, Spain, ⁴Deparment of Pneumology, Hospital Universitario Dr Peset, Valencia, Spain, ⁵Department of Pneumology, Hospital Universitario de Bellvitge, Barcelona, Spain, ⁶Rheumatology Department, Hospital Universitario Doctor Peset, Valencia, Spain
Background/Purpose: Treatment with cyclophosphamide (CYC) for 12 months stabilizes lung function parameters and improves respiratory symptoms of patients with systemic sclerosis and diffuse interstitial lung…
Abstract Number: 294 • 2015 ACR/ARHP Annual Meeting
A Decline in Pulmonary Function over One Year Predicts Outcome in Myositis-Associated Interstitial Lung Disease
Melissa B. Blom¹, Chester V. Oddis², Diane Koontz³ and Rohit Aggarwal⁴, ¹Rheumatology, University of Pittsburgh Medical Center, Pittsburgh, PA, ²Rheum/Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, ³Rheumatology, University of Pittsburgh, Pittsburgh, PA, ⁴Medicine / Rheumatology, University of Pittsburgh, Pittsburgh, PA
Background/Purpose: Interstitial lung disease (ILD) is a leading cause of mortality in myositis. Clinical trials in myositis-associated ILD (MA-ILD) are lacking due to the absence…
Abstract Number: 3134 • 2015 ACR/ARHP Annual Meeting
Safety and Tolerability of Pirfenidone in Patients with Systemic Sclerosis Interstitial Lung Disease
Dinesh Khanna¹, Carlo Albera², Aryeh Fischer³, James R. Seibold⁴, Nader A. Khalidi⁵, Ganesh Raghu⁶, Lorinda Chung⁷, Elena Schiopu¹, Dan Chen⁸ and Eduard Gorina⁹, ¹University of Michigan, Ann Arbor, MI, ²University of Turin, Turin, Italy, ³National Jewish Health and University of Colorado, Denver, CO, ⁴Scleroderma Research Consultants LLC, Litchfield, CT, ⁵McMaster University, Hamilton, ON, Canada, ⁶University of Washington, Seattle, WA, ⁷Division of Immunology and Rheumatology, Stanford University School of Medicine, Stanford, CA, ⁸Jazz Pharmaceuticals (formerly of InterMune), Palo Alto, CA, ⁹Formerly of InterMune, Brisbane, CA
Background/Purpose: Interstitial lung disease (ILD) is a common and serious complication of systemic sclerosis (SSc). Pirfenidone, a novel antifibrotic agent, has been shown to be…
Abstract Number: 307 • 2015 ACR/ARHP Annual Meeting
Screening for Pulmonary Hypertension in the Anti-Synthetase Syndrome; Utility of Four Different Screening Approaches
Helena Andersson¹, Ivar Sjaastad², Thomas Schwartz², Torhild Garen³, T. Mogens Aalokken⁴ and Øyvind Molberg¹, ¹Department of Rheumatology, Institute of Clinical Medicine, Oslo University Hospital, Oslo, Norway, ²Institute for Experimental Medical Research, Oslo University Hospital, Oslo, Norway, ³Rheumatology, Department of Rheumatology, Oslo University Hospital, Oslo, Norway, ⁴Department of Radiology, Oslo University Hospital, Oslo, Norway
Background/Purpose: Pulmonary hypertension (PH) is a feared complication of the anti-synthetase syndrome (ASS) and has previously been reported to occur in 8% of the patients…
Abstract Number: 849 • 2015 ACR/ARHP Annual Meeting
A Computational Tool for Individualized Prognosis of Percent of Predicted Forced Vital Capacity Trajectories in Systemic Sclerosis
Peter Schulam¹, Colin Ligon², Robert Wise³, Laura K. Hummers⁴, Fredrick M. Wigley⁵ and Suchi Saria^1,6, ¹Department of Computer Science, Johns Hopkins University, Baltimore, MD, ²Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ³Department of Pulmonology, Johns Hopkins University School of Medicine, Baltimore, MD, ⁴Johns Hopkins University School of Medicine, Baltimore, MD, ⁵Rheum Div/Mason F Lord, Johns Hopkins University School of Medicine, Baltimore, MD, ⁶Departments of Biostatistics, and Health Policy and Management, Bloomberg School of Public Health, Baltimore, MD
Background/Purpose: Interstitial lung disease (ILD) is a common cause of mortality in systemic sclerosis (Ssc). Decreased forced vital capacity (FVC) in Ssc-ILD is associated with…
Abstract Number: 1075 • 2015 ACR/ARHP Annual Meeting
The Scleroderma Lung Study II (SLS II) Shows That Both Oral Cyclophosphamide (CYC) and Mycophenolate Mofitil (MMF) Are Efficacious in Treating Progressive Interstitial Lung Disease (ILD) in Patients with Systemic Sclerosis (SSc)
Philip J. Clements¹, Donald Tashkin¹, Michael Roth¹, Dinesh Khanna², Daniel E. Furst³, Chi-hong Tseng¹, Elizabeth R. Volkmann¹ and Robert Elashoff⁴, ¹Medicine, University of California Los Angeles, David Geffen School of Medicine, Los Angeles, CA, ²Medicine, University of Michigan, Ann Arbor, MI, ³Medicine, University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, CA, ⁴Biomath, University of California Los Angeles, David Geffen School Of Medicine, Los Angeles, CA
Background/Purpose: Demonstrate that the course of forced vital capacity (FVC) over 2-years was better in SSc patients with symptomatic ILD treated with oral MMF for…
Abstract Number: 1076 • 2015 ACR/ARHP Annual Meeting
Safety and Tolerability of Cyclophosphamide Versus Mycophenolate for Systemic Sclerosis-Related Interstitial Lung Disease
Elizabeth R. Volkmann¹, Michael Roth², Robert Elashoff³, Philip J. Clements¹, Daniel E. Furst², Dinesh Khanna⁴, Jonathan Goldin⁵, Donald Tashkin¹ and Scleroderma Lung Study II Group, ¹Medicine, University of California Los Angeles, David Geffen School of Medicine, Los Angeles, CA, ²Medicine, University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, CA, ³Biomathematics, University of California, Los Angeles, Los Angeles, CA, ⁴Medicine, University of Michigan, Ann Arbor, MI, ⁵David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA
Background/Purpose: Interstitial lung disease (ILD) is the leading cause of death in patients with systemic sclerosis (SSc). Although cyclophosphamide (CYC) demonstrated beneficial treatment effects at…
Abstract Number: 1452 • 2015 ACR/ARHP Annual Meeting
Pauciimmune and Immune Mediated Pulmonary Capillaritis in Children
Jennifer Soares^1,2, Gail Deutsch^2,3, BreAnna Kinghorn² and Anne M. Stevens⁴, ¹Pediatric Pulmonary and Sleep Division, Seattle Children's Hospital, Seattle, WA, ²School of Medicine, University of Washington, Seattle, WA, ³Pathology, Seattle Children's Hospital, Seattle, WA, ⁴Seattle Children's Res Inst, Seattle Children's Hospital, Seattle, WA
Background/Purpose: Immune mediated and pauciimmune pulmonary capillaritis are rare causes of diffuse alveolar hemorrhage and associated childhood diffuse lung disease. As such ideal therapies and…
Abstract Number: 1569 • 2015 ACR/ARHP Annual Meeting
Rituximab Efficacy in the Treatment of Diffuse Interstitial Lung Disease Associated with Rheumatoid Arthritis
Javier Narváez¹, Milagros Ricse², Juan José Alegre³, Gloria Albert Espi³, Carmen Gomez Vaquero⁴, Helena Borrell Paños², Eulalia Armengol², Joan Miquel Nolla², Susana Herrera⁵ and Maria Molina⁶, ¹Rheumatology, Hospital Universitario de Bellvitge, Barcelona, Spain, ²Department of Rheumatology, Hospital Universitario de Bellvitge, Barcelona, Spain, ³Rheumatology Department, Hospital Universitario Doctor Peset, Valencia, Spain, ⁴Department of Rheumatology, Hospital Universitario Bellvitge, Barcelona, Spain, ⁵Deparment of Pneumology, Hospital Universitario Dr Peset, Valencia, Spain, ⁶Department of Pneumology, Hospital Universitario de Bellvitge, Barcelona, Spain
Background/Purpose: To investigate the efficacy and safety of rituximab (RTX) in the the management of progressive rheumatoid arthritis related interstitial lung disease (RA-ILD). Methods: An…
Abstract Number: 1583 • 2015 ACR/ARHP Annual Meeting
Identifying Risk Factors for Progression of Rheumatoid Arthritis-Associated Interstitial Lung Disease
Yashaar Chaichian¹, Dina Bassiri², Imre Noth³, Mary Strek³, Tammy Utset¹ and Rekha Vij³, ¹Medicine, Section of Rheumatology, University of Chicago Medical Center, Chicago, IL, ²Statistical & Applied Research, ACT, Inc., Iowa City, IA, ³Medicine, Section of Pulmonary/Critical Care, University of Chicago Medical Center, Chicago, IL
Background/Purpose: Interstitial lung disease (ILD) is recognized as a frequent extra-articular manifestation of rheumatoid arthritis (RA) associated with significant morbidity and mortality. Nevertheless, risk factors…
Abstract Number: 1590 • 2015 ACR/ARHP Annual Meeting
Rheumatoid Arthritis-Related Interstitial Lung Disease (RA-ILD): Methotrexate and the Extension of Lung Disease Are Associated to Prognosis
Jorge Rojas-Serrano¹, Denisse Herrera-Bringas², Renzo Perez-Dorame³, Mayra Mejia² and Heidegger Mateos-Toledo⁴, ¹Interstitial Lung Diseases Unit, Instituto Nacional de Enfermedades Respiratorias, Mexico City, Mexico, ²Interstitial Lung Diseases Unit, Insituto Nacional de Enfermedades Respiratorias, Mexico, Mexico, ³Intertitial Lung Disease Unit, Instituto Nacional de Enfermedades Respiratorias, Mexico, Mexico, ⁴Interstitial Lung Diseases Unit, Instituto Nacional de Enfermedades Respiratorias, Mexico, Mexico
Background/Purpose:Interstitial lung disease (ILD) is a severe rheumatoid arthritis manifestation with a median survival of 2.6 years. Worst survival has been associated to usual interstitial…
Abstract Number: 1882 • 2015 ACR/ARHP Annual Meeting
The Predictive Value of Pulmonary Function Tests to Diagnose Interstitial Lung Disease in Adults with Early Diffuse Cutaneous Systemic Sclerosis
Elana J. Bernstein¹, Veronica J. Berrocal², Virginia D. Steen³, Victoria K. Shanmugam^4,5, Ami A. Shah⁶, Monique E. Hinchcliff⁷, Faye N. Hant⁸, Jessica K. Gordon⁹, Tracy M. Frech¹⁰, Robyn T. Domsic¹¹, Shervin Assassi¹² and Dinesh Khanna¹³, ¹Rheumatology, Columbia University College of Physicians & Surgeons, New York, NY, ²Div of Rheumatology, University of Michigan, Ann Arbor, MI, ³Rheumatology, Georgetown University Medical Center, Washington, DC, ⁴Division of Rheumatology, The George Washington University, Washington, DC, ⁵Director, Division of Rheumatology, The George Washington University, Washington, DC, ⁶Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ⁷Rheumatology, Northwestern University, Chicago, IL, ⁸Dept of Medicine, Medical University of South Carolina, Charleston, SC, ⁹Rheumatology, Hospital for Special Surgery, New York, NY, ¹⁰Div of Rheumatology, University of Utah, Salt Lake City, UT, ¹¹Medicine - Rheumatology, University of Pittsburgh, Pittsburgh, PA, ¹²Rheumatology, University of Texas Medical School at Houston, Houston, TX, ¹³Division of Rheumatology, University of Michigan, Ann Arbor, MI
Background/Purpose: Interstitial lung disease (ILD) is the leading cause of death in patients with systemic sclerosis (SSc). Patients with diffuse cutaneous systemic sclerosis (dcSSc) have…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].